Diabesity is a term that ties diabetes type II and obesity. Is this the first time youâ€™ve heard about this? I donâ€™t think so. Unfortunately, diabetes prevalence has been on the rise, and it is estimated to be 171 million globally and projected to double this number in the year 2030. Diabesity, as we said before, is the ensemble of an excess of body weight, which will increase the amount of abdominal fat and, lastly, affect insulin resistance.
When we talk about a set of diseases that affect one patient, we must think about the risk that each one of them confers. A progressive multifactorial metabolic disease, characterized by hyperglycemia or high blood glucose and caused by insulin derangements, is what we know as Diabetes. Conversely, diabetes can cause serious complications that can lead to limb amputations caused by macrovascular and microvascular complications, cardiovascular disease or stroke, and renal disease.
On the other hand, obesity has its own set of issues. Still, it has one extra component that we need to talk about: weight gain associated with excess fat that will commonly accumulate in the abdominal area. Excess weight is progressive, and it can be categorized in multiple ranges, the WHO classifies this issue using the Body Mass Index or BMI.
|Nutritional Status||Underweight||Normal weight||Pre-obesity (overweight)||Obesity class I||Obesity class II||Obesity class III|
|BMIÂ kg/m2||below 18.5||18.5-24.9||25.0-29.9||30.0-34.9||35.0-39.9||Above 40|
An excess of body weight has been linked to an imbalance between energy intake and energy expenditure. Hence, an unbalanced high-calorie diet with high sugar foods and no exercise are major key factors that will facilitate extra weight that will escalate until we hit an overweight BMI and then obesity.
Nevertheless, obesity has its own complications: it increases diabetes, coronary heart disease, hypertension, hyperlipidemia, and certain cancers. Diabesity has been liked to chronic stress, increased states of inflammation, oxidative stress, and depression.
Monitoring and prevention
Diagnosis and treatment of diabesity involve the monitoring of blood glucose, measuring the amount of insulin produced by our b-cells in our pancreas, and medication such as insulin, insulin sensitizers (TZDs: rosiglitazone, pioglitazone), insulin secretagogues (sulphonylureas), and modulators of hepatic glucose production (metformin).
Furthermore, diet therapy and exercise are fundamental to the management of this disease. I donâ€™t know if you notice, but the root cause of obesity (weight gain) is the lack of these two components. Hence, the need to start changing a sedentary lifestyle to an active one and increase those veggies in your diet!
Did you know? The US Diabetes Prevention Program showed that reducing 7% body weight through lifestyle changes like moderate physical activity and a calorie-reduced diet decreased the risk of progression and risk of developing diabetes type II.
How can I start reducing my risk or progression of diabesity? From Functional Medicine in Cleveland clinic, Dr. Mark Hyman establishes that optimal management of certain markers will promote better health.
Fasting blood glucose: This is a snapshot of your blood sugar in time. It may not be the best way to monitor our glucose since it’s better to correlate this measurement with HbA1C.
- Normal 65-99Â mg/dL
- Optimal 70-80Â mg/dL
Fasting insulin: Insulin is the hormone that leads our blood glucose to the cells to be metabolized and used for energy in our body. If insulin levels are high for a short period of time, there might be a chance that your blood glucose is not affected. Unfortunately, your blood glucose will be out of range when insulin levels have been on the rise for a prolonged time.
- Normal:Â 2.6âˆ’24.9 Î¼IU/mL
- Optimal: <5Â Î¼IU/mL
- Optimal 1 hour and 2 hours post sugar challenge: <30Â Î¼IU/mL
HbA1C: HbA1C is a measure that monitors the amount of glucose over a long period of time, 6 weeks. Â Â
- NormalÂ 4.8% – 5.6%Â
- Optimal 4.8% – 5.5 %
Lastly, the best way to treat this epidemic disorder is to prevent it. Several authors recommend early screening at 30 years old when the patient is considered at risk: living a sedentary lifestyle and increased waist-to-hip ratio. A healthy lifestyle and monitoring should be installed as the primary line of treatment.
Farag, Youssef MK, and Mahmoud R. Gaballa. “Diabesity: an overview of a rising epidemic.”Â Nephrology Dialysis TransplantationÂ 26.1 (2011): 28-35.
Colagiuri, Stephen. “Diabesity: therapeutic options.”Â Diabetes, Obesity, and MetabolismÂ 12.6 (2010): 463-473.
Hyman, Mark. â€œDiabesity and preventionâ€ Commune, 2020, https://www.onecommune.com/products/hacking-your-healthcare-with-dr-mark-hyman/categories/1666653/posts/5602690.
The information herein on "Diabesity" is not intended to replace a one-on-one relationship with a qualified health care professional, or licensed physician, and is not medical advice. We encourage you to make your own healthcare decisions based on your research and partnership with a qualified healthcare professional.
Our information scope is limited to Chiropractic, musculoskeletal, physical medicines, wellness, contributing etiological viscerosomatic disturbances within clinical presentations, associated somatovisceral reflex clinical dynamics, subluxation complexes, sensitive health issues, and/or functional medicine articles, topics, and discussions.
We provide and present clinical collaboration with specialists from a wide array of disciplines. Each specialist is governed by their professional scope of practice and their jurisdiction of licensure. We use functional health & wellness protocols to treat and support care for the injuries or disorders of the musculoskeletal system.
Our videos, posts, topics, subjects, and insights cover clinical matters, issues, and topics that relate to and support, directly or indirectly, our clinical scope of practice.*
Our office has made a reasonable attempt to provide supportive citations and has identified the relevant research study or studies supporting our posts. We provide copies of supporting research studies available to regulatory boards and the public upon request.
We understand that we cover matters that require an additional explanation of how it may assist in a particular care plan or treatment protocol; therefore, to further discuss the subject matter above, please feel free to ask Dr. Alex Jimenez DC or contact us at 915-850-0900.
We are here to help you and your family.
Dr. Alex Jimenez DC, MSACP, CIFM*, IFMCP*, ATN*, CCST
My Digital Business Card